Trial Profile
A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Antiemetics; Methotrexate; Methylprednisolone
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ITCC-059
- 13 Dec 2022 Results from the ITCC-059 phase IA and phase II trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results (n=30) presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 04 Jun 2021 Planned number of patients changed from 111 to 156.